27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
PD may be a modifiable risk factor for AD, and periodontal interventions could contribute to AD prevention and management. 2 key findings →
Design: case-control study Participants: 52 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Four subtypes were identified: limbic, medial temporal lobe (MTL) sparing, posterior, and lateral temporal (l temporal). 5 key findings →
Participants: 606 Evidence: low
Full summary, score breakdown and related studies → Original source
aECAD was associated with significantly worse scores in processing speed (β = -0.19, p = 0.004) and executive function (β = -0.20, p = 0.009) domains after controlling for age, sex, education, race, and ethnicity. 3 key findings →
Participants: 182 Evidence: low
Full summary, score breakdown and related studies → Original source
Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, cardiovascular disease (CVD), and amyloid- and tau-PET-positive status demonstrated higher p-tau217. 5 key findings →
Participants: 233 Evidence: low
Full summary, score breakdown and related studies → Original source
Both Mann-Whitney tests and ANCOVA found significant differences between groups racialized as AA or NWH with respect to global 11[C]-Pittsburgh Compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness values, p-tau181, and p-tau231 values (p < 0.05). 3 key findings →
Participants: 260 Evidence: low
Full summary, score breakdown and related studies → Original source
When benchmarked against amyloid PET, plasma biomarker-based stratification achieves an optimal balance between diagnostic accuracy and cost-effectiveness. 5 key findings →
Participants: 143 Evidence: low
Full summary, score breakdown and related studies → Original source
Significant interaction effects were observed: MoCA (β = -1.86×10-4, P = 0.006) and PACC (β = -4.0×10-5, P = 0.004), indicating HDL moderates the negative association between NfL and cognition. 3 key findings →
Participants: 417 Evidence: low
Full summary, score breakdown and related studies → Original source
Genetic investigations and associations with plasma biomarkers of dementia with Lewy bodies (DLB) in East Asian populations are lacking. 4 key findings →
Participants: 151 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Over 3.7 years, 22 patients phenoconverted (7 multiple system atrophy [MSA]; 15 Lewy body diseases [LBDs]). 5 key findings →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
Interquartile range differences in amyloid beta 42/40, percent phosphorylated tau 217 (%p-tau217), and Amyloid Probability Score 2 were associated with 1.29 (P = 0.09), 1.38 (P < 0.001), and 1.20 (P = 0.05) increases, respectively, in the hazard of progression from A- to A+ and 0.27 (P = 0.16), 0.50 (P = 0.007), and 0.28 (P = 0.15) Centiloid/year increases, respectively, in annual rate of amyloid PET change. 5 key findings →
Participants: 290 Evidence: low
Full summary, score breakdown and related studies → Original source
Using a panel of biomarkers was significantly better at predicting disease stage compared with p-tau217 alone; however, the difference was dependent upon p-tau217 assay. 5 key findings →
Participants: 387 Evidence: low
Full summary, score breakdown and related studies → Original source
Digital cognitive testing using online platforms has emerged as a potentially transformative tool in clinical neuroscience. 3 key findings →
Participants: 325 Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundEarly diagnosis of early-onset dementia (EOD) is often challenging. 1 key finding →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source
Among all participants (mean age 66.7 ± 6.5 years, 100% non-Hispanic White), 451 (6.6%) were using statins at baseline. 5 key findings →
Participants: 564 Evidence: low
Full summary, score breakdown and related studies → Original source
Ninety-four proteins differentiated in the high-risk group compared to low-risk (p < 0.05), none surviving FDR correction. 5 key findings →
Participants: 156 Evidence: moderate
Full summary, score breakdown and related studies → Original source
With aging, the hippocampal formation shows variable structural atrophy, which is associated with a decline in cognitive performance. 5 key findings →
Participants: 661 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 260 AD deaths occurred during a median follow-up of 9.8 years. 5 key findings →
Participants: 27,773 Evidence: low
Full summary, score breakdown and related studies → Original source
We identified 59 key microbial species linked to MCI and AD biomarkers. 5 key findings →
Participants: 119 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A diagnostic rubric is required to distinguish between limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). 3 key findings →
Participants: 514 Evidence: low
Full summary, score breakdown and related studies → Original source
Of 162 034 eligible Medicare beneficiaries (mean [SD] age, 85.0 [7.9] years; 94 304 female [58.2%]), 51 191 (31.6%) were attributed to MSSP ACO. 2 key findings →
Design: cohort Participants: 162,034 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. 2 key findings →
Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Novel plasma assays enabled accurate blood-based biomarkers for neurodegenerative diseases with minimally invasive options for clinical use. 5 key findings →
Participants: 3,232 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The findings suggest that permeability of the blood-brain barrier is linked to AD pathophysiology, contributes to cerebrovascular lesions observed on MRI, and is associated with neuroinflammation in middle age. 5 key findings →
Participants: 488 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Observational studies and pilot trials suggest that metformin may help prevent cognitive decline in neurodegenerative disorders. 3 key findings →
Participants: 326 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We are currently in the recruitment and data collection phase. 1 key finding →
Design: cohort study Participants: 1,307 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →